SCHEMBL644279

SCHEMBL644279

O=C(O)CC1CCCCN1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 2/20 0.52
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
LMNA P02545 2/20 0.49
TP53 P04637 2/20 0.49
MITF O75030 1/20 0.49
CYP3A4 P08684 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NLRP1 Q9C000 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
CYP2D6 P10635 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
MLNR O43193 1/20 0.47
ABCB11 O95342 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288736 1.00 FDPS (0.52) FDPSKMT2AMEN1LMNATP53
SCHEMBL5782951 1.00 FDPS (0.52) FDPSKMT2AMEN1LMNATP53
SCHEMBL5499053 0.98 KMT2A (0.51) FDPSKMT2AMEN1LMNATP53
Hydrochloric Acid SCHEMBL16909535 0.98 FDPS (0.50) FDPSKMT2AMEN1LMNATP53
Hydrochloric Acid SCHEMBL645809 0.98 FDPS (0.50) FDPSKMT2AMEN1LMNATP53
Hydrochloric Acid SCHEMBL16909729 0.98 FDPS (0.50) FDPSKMT2AMEN1LMNATP53
Oxalic Acid SCHEMBL28807941 0.96 FDPS (0.49) FDPSKMT2AMEN1LMNATP53
SCHEMBL288786 0.93
SCHEMBL1476244 0.93
SCHEMBL288677 0.93

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 305 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119330874-A Parsley alkaloid, hybridoma cell strain, antibody and application 江南大学 2025-01-21 CN claimed
CN-112566900-B Immunomodulator, composition and preparation method thereof 贝达药业股份有限公司 2024-04-26 CN claimed
CN-112424194-B Immunomodulator, composition and preparation method thereof 贝达药业股份有限公司 2024-02-06 CN claimed
CN-117050061-A 2,4, 6-tri (piperidinecarboxylic acid) -1,3,5 triazine and preparation method thereof 济南利恒生物科技有限公司 2023-11-14 CN claimed
CN-113603886-A Polyethyleneimine derivative and preparation method and application thereof 中国科学院长春应用化学研究所 2021-11-05 CN claimed
CN-102216279-B Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof TOPHARMAN SHANGHAI Co.,Ltd. (CN) 2014-10-29 CN claimed
CN-100508975-C Use of pyrazolopyridine compound ASTELLAS PHARMA INC (JP) 2009-07-08 CN claimed
US-20050075270-A1 Process for preparation of piperidin-2-ylacetic acid FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-04-07 US claimed
EP-1426359-A1 PROCESS FOR PREPARATION OF PIPERIDIN-2-YLACETIC ACID FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-09 EP claimed
JP-8333339-A None JP disclosed
EP-4731266-A1 NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES The Regents of the University of Michigan (US) 2026-04-29 EP disclosed
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2026-04-23 US disclosed
US-12600909-B2 Etching solution composition RASA INDUSTRIES, LTD. (JP) 2026-04-14 US disclosed
US-12569565-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2026-03-10 US disclosed
EP-0497258-A2 Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-08-05 EP disclosed
US-4943635-A OXAZABOROLIDINES AND OXAZABORINES AS CATALYSTS PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) 1990-07-24 US disclosed
EP-0305180-A2 Enantioselective reduction of ketones THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 1989-03-01 EP disclosed
US-4402961-A Derivatives of 1-(2-,3- or 4-quinolyl)-2- or -3-(2- or 3-piperidyl or -pyrrolidinyl) ethanone or propanone, and their utilization as antiarrhythmics, anticonvulsivants and for the treatment of anxiety PHARMINDUSTRIE (FR) 1983-09-06 US disclosed
US-4217238-A BASIC SALT, SCRUBBING EXXON RESEARCH & ENGINEERING CO. (US) 1980-08-12 US disclosed
US-4094957-A CARBON DIOXIDE EXXON RESEARCH & ENGINEERING CO. (US) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260108618-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, FCGR1A, FCGR2A FDPS 4033/4885KMT2A 1692/4885MEN1 4679/4885
US-12569565-B2 Compositions and methods for the treatment of viral infections ALB, FCGR3B, FCGR1A FDPS 3656/4885KMT2A 1639/4885MEN1 3799/4885
US-12600909-B2 Etching solution composition ASIC3, GRIN2D, ASIC1 FDPS 2037/4885KMT2A 1013/4885MEN1 3125/4885
US-20050075270-A1 Process for preparation of piperidin-2-ylacetic acid CIP2A, TPH2, TET2 FDPS 4590/4885KMT2A 24/4885MEN1 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.